Dr. Jason Westin on Combination Targeted Therapy Prior to Chemotherapy for DLBCL

Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.

Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.

Related Content:

American Society of Clinical Oncology Annual Meeting (ASCO)LeukemiaDiffuse Large B-Cell LymphomaLymphoma
Expert Details ‘Exciting’ Bispecific Combos for Lymphoma
Selecting an Appropriate BTK Inhibitor for the Treatment of Relapsed CLL
Comparing BTK Inhibitors in the Treatment of Relapsed CLL